The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Research Report 2024
Synopsis
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
The global VPM1002 (Tuberculosis BCG Based Vaccine) market was valued at US$ 373.7 million in 2023 and is anticipated to reach US$ 474.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for VPM1002 (Tuberculosis BCG Based Vaccine), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VPM1002 (Tuberculosis BCG Based Vaccine).
Report Scope
The VPM1002 (Tuberculosis BCG Based Vaccine) market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VPM1002 (Tuberculosis BCG Based Vaccine) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VPM1002 (Tuberculosis BCG Based Vaccine) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vakzine Projekt Management (VPM)
Serum Institute of India
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of VPM1002 (Tuberculosis BCG Based Vaccine) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of VPM1002 (Tuberculosis BCG Based Vaccine) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
The global VPM1002 (Tuberculosis BCG Based Vaccine) market was valued at US$ 373.7 million in 2023 and is anticipated to reach US$ 474.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for VPM1002 (Tuberculosis BCG Based Vaccine), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VPM1002 (Tuberculosis BCG Based Vaccine).
Report Scope
The VPM1002 (Tuberculosis BCG Based Vaccine) market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VPM1002 (Tuberculosis BCG Based Vaccine) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VPM1002 (Tuberculosis BCG Based Vaccine) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vakzine Projekt Management (VPM)
Serum Institute of India
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of VPM1002 (Tuberculosis BCG Based Vaccine) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of VPM1002 (Tuberculosis BCG Based Vaccine) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 VPM1002 (Tuberculosis BCG Based Vaccine) Market Overview
1.1 Product Overview and Scope of VPM1002 (Tuberculosis BCG Based Vaccine)
1.2 VPM1002 (Tuberculosis BCG Based Vaccine) Segment by Dosage
1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Dosage (2024-2030)
1.2.2 0.5ml Package
1.2.3 1ml Package
1.2.4 2ml Package
1.2.5 Other
1.3 VPM1002 (Tuberculosis BCG Based Vaccine) Segment by Application
1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value by Application: (2024-2030)
1.3.2 0-5 Years Old
1.3.3 5-18 Years Old
1.3.4 18-45 Years Old
1.3.5 45-65 Years Old
1.3.6 ≥65 Years Old
1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Estimates and Forecasts
1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue 2019-2030
1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales 2019-2030
1.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Competition by Manufacturers
2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Manufacturers (2019-2024)
2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Average Price by Manufacturers (2019-2024)
2.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Product Type & Application
2.7 VPM1002 (Tuberculosis BCG Based Vaccine) Market Competitive Situation and Trends
2.7.1 VPM1002 (Tuberculosis BCG Based Vaccine) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) Players Market Share by Revenue
2.7.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VPM1002 (Tuberculosis BCG Based Vaccine) Retrospective Market Scenario by Region
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2019-2030
3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2019-2024
3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2025-2030
3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2019-2030
3.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2019-2024
3.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2025-2030
3.4 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.4.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2030)
3.4.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.5.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2030)
3.5.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.6.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2030)
3.6.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.7.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2030)
3.7.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.8.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2030)
3.8.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2019-2030)
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2019-2024)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2025-2030)
4.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2019-2030)
4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2019-2030)
4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2019-2024)
4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2025-2030)
4.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2019-2030)
4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type (2019-2030)
5 Segment by Application
5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2019-2030)
5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2019-2024)
5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2025-2030)
5.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2019-2030)
5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2019-2030)
5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2019-2024)
5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2025-2030)
5.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2019-2030)
5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Vakzine Projekt Management (VPM)
6.1.1 Vakzine Projekt Management (VPM) Corporation Information
6.1.2 Vakzine Projekt Management (VPM) Description and Business Overview
6.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product Portfolio
6.1.5 Vakzine Projekt Management (VPM) Recent Developments/Updates
6.2 Serum Institute of India
6.2.1 Serum Institute of India Corporation Information
6.2.2 Serum Institute of India Description and Business Overview
6.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product Portfolio
6.2.5 Serum Institute of India Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Chain Analysis
7.2 VPM1002 (Tuberculosis BCG Based Vaccine) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VPM1002 (Tuberculosis BCG Based Vaccine) Production Mode & Process
7.4 VPM1002 (Tuberculosis BCG Based Vaccine) Sales and Marketing
7.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) Sales Channels
7.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) Distributors
7.5 VPM1002 (Tuberculosis BCG Based Vaccine) Customers
8 VPM1002 (Tuberculosis BCG Based Vaccine) Market Dynamics
8.1 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Trends
8.2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
8.3 VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
8.4 VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Competitive Situation by Manufacturers in 2023
Table 4. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) of Key Manufacturers (2019-2024)
Table 5. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market VPM1002 (Tuberculosis BCG Based Vaccine) Average Price (USD/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of VPM1002 (Tuberculosis BCG Based Vaccine), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Product Type & Application
Table 12. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2019-2024) & (K Doses)
Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2019-2024)
Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2025-2030) & (K Doses)
Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2025-2030)
Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2019-2024)
Table 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2025-2030)
Table 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2024) & (K Doses)
Table 27. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2025-2030) & (K Doses)
Table 28. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2024) & (K Doses)
Table 32. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2025-2030) & (K Doses)
Table 33. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2019-2024) & (K Doses)
Table 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2025-2030) & (K Doses)
Table 38. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2024) & (K Doses)
Table 42. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2025-2030) & (K Doses)
Table 43. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2024) & (K Doses)
Table 47. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2025-2030) & (K Doses)
Table 48. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Type (2019-2024)
Table 51. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Type (2025-2030)
Table 52. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2019-2024)
Table 53. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2025-2030)
Table 54. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2019-2024)
Table 57. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2025-2030)
Table 58. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2019-2024)
Table 59. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2025-2030)
Table 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Application (2019-2024)
Table 61. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Application (2025-2030)
Table 62. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2019-2024)
Table 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2025-2030)
Table 64. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2019-2024)
Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2025-2030)
Table 68. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2019-2024)
Table 69. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2025-2030)
Table 70. Vakzine Projekt Management (VPM) Corporation Information
Table 71. Vakzine Projekt Management (VPM) Description and Business Overview
Table 72. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 73. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product
Table 74. Vakzine Projekt Management (VPM) Recent Developments/Updates
Table 75. Serum Institute of India Corporation Information
Table 76. Serum Institute of India Description and Business Overview
Table 77. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 78. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product
Table 79. Serum Institute of India Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. VPM1002 (Tuberculosis BCG Based Vaccine) Distributors List
Table 83. VPM1002 (Tuberculosis BCG Based Vaccine) Customers List
Table 84. VPM1002 (Tuberculosis BCG Based Vaccine) Market Trends
Table 85. VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
Table 86. VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
Table 87. VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of VPM1002 (Tuberculosis BCG Based Vaccine)
Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Type in 2023 & 2030
Figure 4. 0.5ml Package Product Picture
Figure 5. 1ml Package Product Picture
Figure 6. 2ml Package Product Picture
Figure 7. Other Product Picture
Figure 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Application in 2023 & 2030
Figure 10. 0-5 Years Old
Figure 11. 5-18 Years Old
Figure 12. 18-45 Years Old
Figure 13. 45-65 Years Old
Figure 14. ≥65 Years Old
Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size (2019-2030) & (US$ Million)
Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (2019-2030) & (K Doses)
Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Average Price (USD/Dose) & (2019-2030)
Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) Report Years Considered
Figure 20. VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Manufacturers in 2023
Figure 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) Players: Market Share by Revenue in 2023
Figure 23. VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2019-2030)
Figure 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2019-2030)
Figure 27. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2019-2030)
Figure 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2019-2030)
Figure 31. Germany VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2019-2030)
Figure 38. China VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2019-2030)
Figure 49. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2019-2030)
Figure 50. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2019-2030)
Figure 55. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Type (2019-2030)
Figure 59. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Type (2019-2030)
Figure 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2019-2030)
Figure 61. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Application (2019-2030)
Figure 62. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Application (2019-2030)
Figure 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2019-2030)
Figure 64. VPM1002 (Tuberculosis BCG Based Vaccine) Value Chain
Figure 65. VPM1002 (Tuberculosis BCG Based Vaccine) Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
